Mein Warenkorb

DXD

DXD Produktliste

  • Attribut

    Antibody (3)

  • Produktbibliothek

    Online (3)

  • Spezies

    Mouse (3)

  • Etikett

    - (3)

  • Marker

    Unconjugated (1)HRP Labeled (1)Biotin-labeled (1)

DXD Molekülhintergrund

Dxd (Exatecan ADC derivative) is a potent DNA topoisomerase I inhibitor with an IC50 of 0.31 uM for targeting ADCs (DS-8201A). Dxd was cytotoxic to human tumor cell lines KPL-4, NCI-N87 and SK-BR, 3 and the IC50s of MDA-MB-468 was 1.43 NM-4.07 nM, while lgGADC (Dxd as payload) had no inhibitory effect on HER2 expression in the 4 cell lines. DS8201a (Dxd as payload) had a significant inhibitory effect on HER2-positive KPL-4 and NCI cell lines N87 and SK-BRwith IC50 values of 26.8, 25.4 and 6.7 ng/mL, respectively, but had no inhibitory effect on MDA MB-468 (IC50, > 10000 - mL). HRP-anti-DXD-antibody is a conjugation product of HRP and anti-DXD-antibody. It can be used in PK, PD analysis and ELISA.

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
TifcemalimabTAB-004; JS-004Phase 3 ClinicalShanghai Junshi Biosciences Co LtdSolid tumours; Head and Neck Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Hodgkin Disease; Nasopharyngeal Carcinoma; Lymphoma; Lung Neoplasms; Melanoma; Neoplasm Metastasis
Details
ANB-032ANB-032Phase 2 ClinicalAnaptysbio IncInflammation; Dermatitis, Atopic; Eczema
Details
VenanprubartLY-3361237Phase 2 ClinicalSanford-Burnham Medical Research Institute, Eli Lilly And CompanySjogren's Syndrome; Lupus Erythematosus, Systemic; Psoriasis
Details
MB-272MB272; GS-0272Phase 1 ClinicalUniversity Of OxfordArthritis, Rheumatoid; Autoimmune Diseases; Lupus Erythematosus, Systemic
Details
HFB-200603HFB-200603Phase 1 ClinicalHiFiBiO TherapeuticsCarcinoma, Renal Cell; Stomach Neoplasms; Neoplasms; Colorectal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung
Details
  • Produktliste
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns